Pharmaceutical Substances Syntheses, Patents, Applications - Part 19. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers | Batroxobin B 181 V 1. OIC HOBt 2. separation of diastereomers by crystal izotion Barnidipine Reference s a DE 2 904 552 Yamanouchi Pharm. appl. J-prior. . b CN 85 107 590 Faming Zhuanli Sheqing Gonhai S. appl. J-prior. . alternative syntheses Hirose Y Kariya K. Sasaki I. Kuronom Y Achiwa K. Tetrahedron Lett. TELEAY 34 37 5915 1993 . JP 6 279 409 Mercian Corp. J-prior. . JP 7 070 066 Amano Pharma Co. prior. . alternative synthesis of optically active l-benzyl-3-hydroxypyrrolidine JP9 263 578 Koei Chemical Co. appl. . X-ray structure and synthesis of all enantiomers Tamazawa K ct al. J. Med. Chem. JMCMAR 29 12 2504 1986 Formulation s tabl. 5 mg 10 mg 15 mg as hydrochloride Trade Name s J Hypoca R Yamanouchi 1992 Batroxobin ATC B02BX03 Use anticoagulant fibrinolytic RN 9039-61-6 MF unspecified LDS0 384 pg kg M . 210 pg kg R . 380 pg kg dog . CN bothrops atrox serine proteinase MW unspecified EINECS 232-918-4 Fibrinolytic effecting protease enzyme from the poison secretion venom of Bothrops atrox with glycoprotein structure. It has thrombin similarly endopeptidase activity. Purification by chromatographic methods. Reference s US 3 849 252 Pentapharm CH-prior. . DOS 2201 993 Pentapharm appl. CH-prior. . Formulation s amp. 20 iu. Trade Name s I Botropase Ravizza J Defibrase Tobishi- Reptilase Lepetit Fujisawa 182 B Beclamide Beclamide ATC NO3AX3O Use antiepileptic anticonvulsant RN 501-68-8 MF C10H12C1NO MW EINECS 207-927-1 LD5o 1 g kg M . 770 mg kg R . 3200 mg kg R . CN 3-chloro-7V- phenylmethyl propanamide benzylamine 3-chloropropionyl chloride NaOH Beclamide Reference s US 2 569 288 American Cyanamid 1951 prior. 1949 . Formulation s drg. 330 mg 500 mg Trade Name s D Neuracen Promonta wfm Posedrin Promonta wfm F Posedrine Aron wfm GB Nydrane Rona wfm I Posedrine Aron wfm Beclobrate atc bo4ac Use hyperlipidemic RN 55937-99-0 MF C2 .
